Brand Names:
Baytril, Enrotril


Drug Type: Antibiotic

Enrofloxacin (Baytril, Enrotril)


Enrofloxacin (Baytril, Enrotril) is a fluroquinolone, broad-spectrum antibiotic which is useful for treating a wide range of bacterial infections in birds. Baytril is the veterinary-labeled form of ciprofloxacin, which is the equivalent drug used for humans. Fluroquinolone antibiotics are the drug of choice against Mycoplasma, some gram-positive bacteria, and most gram-negative bacteria (includes Escherichia coli, and Salmonella). The oral syrup can be given directly to the mouth or dissolved in the drinking water. Due to its bitter taste, it may be necessary to mix the drug with another medium such as apple sauce or fruit juice to improve the taste. The drug is less effective when administered in drinking water.

Caution: May cause muscle necrosis and pain at the injection site if given IM. Repeated IM injections are not recommended. Birds taking this medication should be concurrently monitored for signs of secondary infections.
available in tablet form, as an injection and as an oral syrup.
10-15 mg/kg PO, SC, IM q12-24h | For chickens, 50 mg/L drinking water | For ducks, 50 mg/kg via nebulization x 4h (Day 1, AM) then 25 mg/kg x 4h/day x 4 days.
  • May cause muscle necrosis and pain at the injection site if given IM. Repeated IM injections are not recommended.
  • Behavioral changes
  • Secondary infections
  • Acetylsalicylic acid (Asprin): Acetylsalicylic acid may increase the neuroexcitatory activities of Enrofloxacin.
  • Betamethasone: The risk or severity of adverse effects can be increased when Betamethasone is combined with Enrofloxacin.
  • Calcium products: Calcium Acetate can cause a decrease in the absorption of Enrofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
  • Calcium Acetate can cause a decrease in the absorption of Enrofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
  • Carprofen: Carprofen may increase the neuroexcitatory activities of Enrofloxacin.
  • Chloroquine: Enrofloxacin may increase the QTc-prolonging activities of Chloroquine.
  • Chlorpromazine: Chlorpromazine may increase the QTc-prolonging activities of Enrofloxacin.
  • Corticosterone: The risk or severity of adverse effects can be increased when Corticosterone is combined with Enrofloxacin.
  • Curcumin: Curcumin may increase the neuroexcitatory activities of Enrofloxacin.
  • Dexamethasone
  • The risk or severity of adverse effects can be increased when Dexamethasone is combined with Enrofloxacin.
  • Diclofenac:Diclofenac may increase the neuroexcitatory activities of Enrofloxacin.
  • Digitoxin: Digitoxin may decrease the cardiotoxic activities of Enrofloxacin.
  • Digoxin: Digoxin may decrease the cardiotoxic activities of Enrofloxacin.
  • Enalapril: The risk or severity of ventricular arrhythmias can be increased when Enalapril is combined with Enrofloxacin.
  • Erythromycin: Erythromycin may increase the QTc-prolonging activities of Enrofloxacin.
  • Etodolac: Etodolac may increase the neuroexcitatory activities of Enrofloxacin.
  • Evening primrose oil:Evening primrose oil may increase the neuroexcitatory activities of Enrofloxacin.
  • Fluconazole:Fluconazole may increase the QTc-prolonging activities of Enrofloxacin.
  • Flunixin: Flunixin may increase the neuroexcitatory activities of Enrofloxacin.
  • Hydrocortisone: The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Enrofloxacin.
  • Iron: The serum concentration of Enrofloxacin can be decreased when it is combined with Iron.
  • Isoflurane:Isoflurane may increase the QTc-prolonging activities of Enrofloxacin.
  • Itraconazole: Itraconazole may increase the QTc-prolonging activities of Enrofloxacin.
  • Ketoconazole: Ketoconazole may increase the QTc-prolonging activities of Enrofloxacin.
  • Ketoprofen: Ketoprofen may increase the neuroexcitatory activities of Enrofloxacin.
  • Leuprolide: Leuprolide may increase the QTc-prolonging activities of Enrofloxacin.
  • Magnesium sulfate: The serum concentration of Enrofloxacin can be decreased when it is combined with Magnesium sulfate.
  • Meloxicam: Meloxicam may increase the neuroexcitatory activities of Enrofloxacin.
  • Methylprednisolone: The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Enrofloxacin.
  • Naproxen: Naproxen may increase the neuroexcitatory activities of Enrofloxacin.
  • Oxytocin:Oxytocin may increase the QTc-prolonging activities of Enrofloxacinn.
  • Pergolide: The risk or severity of adverse effects can be increased when Pergolide is combined with Enrofloxacin.
  • Phenylbutazone: Phenylbutazone may increase the neuroexcitatory activities of Enrofloxacin.
  • Prednisolone:The risk or severity of adverse effects can be increased when Prednisolone is combined with Enrofloxacin.
  • Prednisone: The risk or severity of adverse effects can be increased when Prednisone is combined with Enrofloxacin.
  • Resveratrol:Resveratrol may increase the neuroexcitatory activities of Enrofloxacin.
  • Sodium bicarbonate:Sodium bicarbonate can cause a decrease in the absorption of Enrofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
  • Sulfadiazine:Enrofloxacin may increase the hypoglycemic activities of Sulfadiazine
  • Sulfamethoxazole:Sulfamethoxazole may increase the QTc-prolonging activities of Enrofloxacin.
  • Tamoxifen:Tamoxifen may increase the QTc-prolonging activities of Enrofloxacin.
  • Trimethoprim:Trimethoprim may increase the QTc-prolonging activities of Enrofloxacin.
  • Voriconazole: Voriconazole may increase the QTc-prolonging activities of Enrofloxacin.
  • Xanthinol:The serum concentration of Xanthinol can be increased when it is combined with Enrofloxacin.